Skip to nav Skip to content
Tiago  Biachi

Tiago Biachi, MD, PhD

4.9 (107)

Specialty: Medical Oncology

Program: Gastrointestinal Oncology

Language(s): English

  • Overview

    Cancer Focus:
    Colorectal Cancer, Pancreatic Cancer

    Dr. Tiago Biachi de Castria is an Associate Member in the Department of Gastrointestinal Oncology at Moffitt Cancer Center. Dr. Biachi de Castria received his MD degree from Universidade Federal de Ciências da Saúde de Porto Alegre, Brazil. He also obtained a Doctorate degree in Internal Medicine and Therapeutics from São Paulo Federal University. He completed his Residency in Internal Medicine at São Paulo Federal University and his Clinical Oncology Fellowship at the São Paulo University - São Paulo Cancer Institute. Dr. Biachi de Castria was an attending in the Gastrointestinal Oncology Service at the São Paulo Cancer Institute and Sírio-Libanês Hospital. In 2021, he obtained the title of Associate Professor in Gastroenterology Service (São Paulo University) and Associate Professor in Postgraduate Course in Medical Oncology (São Paulo University). Dr. Biachi de Castria most recently completed a one-year Advanced Fellowship in Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center. Dr. Tiago Biachi de Castria’s clinical interest is in colorectal and upper GI cancers, including gastroesophageal and Hepatopancreatobiliary (HPB). His research interest is colorectal cancer, including biomarkers and drug development.

  • Participating Trials

    Clinical Trial 21220
    A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors
    Condition: Gastrointestinal Tumor
    Intervention: 5-fluorouracil (); FOLFIRINOX (); Oxaliplatin (); Pembrolizumab (Keytruda); Taxotere (docetaxel); docetaxel (); eloxatin (Oxaliplatin); leucovorin (); mRNA-4157 ()
    Status: Open

    Clinical Trial 21513
    A Phase 1 Study of KZR-261, a Small Molecule Sec61 Inhibitor, in Subjects with Advanced Solid Malignancies
    Condition: Multiple
    Intervention: KZR-261 ()
    Status: Open

    Clinical Trial 22565
    Evaluation of the clinical outcomes of immune checkpoint blockade in MUTYH associated colorectal cancer patients.
    Condition: Gastrointestinal Tumor
    Status: Open

    Clinical Trial 23233
    Evaluating the correlation between clonal hematopoiesis chemotherapy induced peripheral neuropathy in patients with gastrointestinal malignancies exposed to oxaliplatin
    Condition: Gastrointestinal Tumor
    Status: Open

    If you believe you are eligible for one of these trials or studies, please call
    813-745-6100 or toll-free 1-800-679-0775.

  • Publications

    • Protásio BM, de Castria TB, Natalino R, Mangone FR, Saragiotto DF, Sabbaga J, Hoff PM, Chammas R. Prognostic Impact of Primary Tumor Sidedness in Stage III Colorectal Cancer: Real-World Evidence from a Brazilian Cohort. Clin Colorectal Cancer. 2024 Mar.23(1):73-84. Pubmedid: 38151358.
    • de Moraes FCA, Pasqualotto E, Chavez MP, Ferreira ROM, De Castria TB, Burbano RMR. Efficacy and safety of Zolbetuximab plus chemotherapy for advanced CLDN18.2-positive gastric or gastro-oesophageal adenocarcinoma: a meta-analysis of randomized clinical trials. BMC Cancer. 2024 Feb.24(1):240. Pubmedid: 38383390. Pmcid: PMC10882870.
    • Turner K, Kim DW, Gonzalez BD, Gore LR, Gurd E, Milano J, Riccardi D, Byrne M, Al-Jumayli M, de Castria TB, Laber DA, Hoffe S, Costello J, Robinson E, Chadha JS, Rajasekhara S, Hume E, Hagen R, Nguyen OT, Nardella N, Parker N, Carson TL, Tabriz AA, Hodul P. Support Through Remote Observation and Nutrition Guidance (STRONG), a digital health intervention to reduce malnutrition among pancreatic cancer patients: A study protocol for a pilot randomized controlled trial. Contemp Clin Trials Commun. 2024 Apr.38:101271. Pubmedid: 38440777. Pmcid: PMC10910065.
    • Biachi de Castria T, Miao R, Kim RD. Fruquintinib in Patients with Previously Treated Metastatic Colorectal Cancer. touchREVIEWS in Oncology & Haematology. 2024 Apr.20(1).
    • Abou-Alfa GK, Afihene M, Capanu M, Li Y, Chou JF, Asombang A, Alatise OI, Bounedjar A, Cunha L, Mekonnen HD, Diop PS, Elwakil R, Ali MM, Ndlovu N, Ndumbalo J, Makondi PT, Tzeuton C, Biachi de Castria T, Agyei-Nkansah AA, Balogun F, Bougouma A, Atipo Ibara BI, Jonas E, Kimani S, Kingham P, Kurrimbukus R, Hammad N, Fouad M, El Baghdady N, Servais Albert Fiacre EB, Sewram V, Spearman CW, Yang JD, Roberts LR, Abdelaziz AO. Africa Guidelines for Hepatocellular Carcinoma Buildup Process. JCO Glob Oncol. 2023 Sep.9:e2300159. Pubmedid: 37944087. Pmcid: PMC10645406.
    • Khasawneh H, Ferreira Dalla Pria HR, Miranda J, Nevin R, Chhabra S, Hamdan D, Chakraborty J, Biachi de Castria T, Horvat N. CT Imaging Assessment of Pancreatic Adenocarcinoma Resectability after Neoadjuvant Therapy: Current Status and Perspective on the Use of Radiomics. J Clin Med. 2023 Oct.12(21). Pubmedid: 37959287. Pmcid: PMC10649102.
    • Queiroz MM, Lima NF, Biachi de Castria T. Immunotherapy and Targeted Therapy for Advanced Biliary Tract Cancer: Adding New Flavors to the Pizza. Cancers (Basel). 2023 Mar.15(7). Pubmedid: 37046631. Pmcid: PMC10093144.
    • Capareli F, Costa F, Tuszynski JA, Sousa MC, Setogute YC, Lima PD, Carvalho L, Santos E, Gumz BP, Sabbaga J, de Castria TB, Jardim DL, Freitas D, Horvat N, Bezerra ROF, Testagrossa L, Costa T, Zanesco T, Iemma AF, Abou-Alfa GK. Low-energy amplitude-modulated electromagnetic field exposure: Feasibility study in patients with hepatocellular carcinoma. Cancer Med. 2023 Jun.12(11):12402-12412. Pubmedid: 37184216. Pmcid: PMC10278519.
    • Maron SB, Chatila W, Walch H, Chou JF, Ceglia N, Ptashkin R, Do RKG, Paroder V, Pandit-Taskar N, Lewis JS, Biachi De Castria T, Sabwa S, Socolow F, Feder L, Thomas J, Schulze I, Kim K, Elzein A, Bojilova V, Zatzman M, Bhanot U, Nagy RJ, Lee J, Simmons M, Segal M, Ku GY, Ilson DH, Capanu M, Hechtman JF, Merghoub T, Shah S, Schultz N, Solit DB, Janjigian YY. Determinants of survival in HER2+ metastatic esophagogastric cancer. Clin Cancer Res. 2023 Jul. Pubmedid: 37406106.
    • Webking S, Sandoval ML, Chuong MD, Ucar A, Aparo S, De Zarraga F, Sahin I, Biachi T, Kim DW, Hoffe SE, Frakes JM, Palm RF. Ablative 5-Fraction Stereotactic MRI-Guided Adaptive Radiotherapy for Oligometastatic Pancreatic Adenocarcinoma. Cancer Control. 2023 Jan.30. Pubmedid: 38038261. Pmcid: PMC10693219.
    • Yan T, Huang C, Peng C, Duan X, Ji D, Duan Y, Zhang W, Zhao H, Gao K, Yang X, Zhang L, Cheng J, de Castria TB, Pocha C, Tsilimigras DI, Wu T, Su G, Li Y, Yu L, Lu Y. A multi-center retrospective study on the efficacy and safety of regorafenib vs. regorafenib combined with PD-1 inhibitors as a second-line therapy in patients with advanced hepatocellular carcinoma. Ann Transl Med. 2023 Jan.11(2):109. Pubmedid: 36819518. Pmcid: PMC9929741.
    • Li J, Zhang D, Liu H, Wang D, Pan C, Biachi de Castria T, Mok SRS, Zhou Z, Yan C. Identification of potential prognostic biomarkers among gene models for coiled-coil domain-containing family members in hepatocellular carcinoma elucidates their influence on the hypoxia pathway and immune microenvironment. J Gastrointest Oncol. 2023 Dec.14(6):2559-2573. Pubmedid: 38196528. Pmcid: PMC10772702.
    • Miranda J, Causa Andrieu P, Nincevic J, Gomes de Farias LP, Khasawneh H, Arita Y, Stanietzky N, Fernandes MC, De Castria TB, Horvat N. Advances in MRI-Based Assessment of Rectal Cancer Post-Neoadjuvant Therapy: A Comprehensive Review. J Clin Med. 2023 Dec.13(1). Pubmedid: 38202179. Pmcid: PMC10780006.
    • de Castria TB, Khalil DN, Harding JJ, O'Reilly EM, Abou-Alfa GK. Tremelimumab and durvalumab in the treatment of unresectable, advanced hepatocellular carcinoma. Future Oncol. 2022 Oct.18(33):3769-3782. Pubmedid: 36399155.
    • Huang E, Ma T, Zhou J, Ma N, Yang W, Liu C, Hou Z, Chen S, de Castria TB, Zeng B, Zong Z, Zhou T. The development and validation of a novel senescence-related long-chain non-coding RNA (lncRNA) signature that predicts prognosis and the tumor microenvironment of patients with hepatocellular carcinoma. Ann Transl Med. 2022 Jul.10(14):766. Pubmedid: 35965795. Pmcid: PMC9372681.
    • Pereira MA, Ramos MFKP, Dias AR, Ribeiro R, Cardili L, Zilberstein B, Cecconello I, Ribeiro U, de Mello ES, de Castria TB. Scoring systems for PD-L1 expression and their prognostic impact in patients with resectable gastric cancer. Virchows Arch. 2021 Jun.478(6):1039-1048. Pubmedid: 33098489.
    • Dornellas AFL, Ramos MFKP, Pereira MA, Cardili L, Dias AR, de Castria TB. Locally Advanced Gastric Adenocarcinoma with Impressive Response to Hemostatic Radiation: the Possible Role of p53 Status and Eosinophilic Infiltrate. J Gastrointest Cancer. 2021 Jun.52(2):788-791. Pubmedid: 32954464.
    • Pereira MA, de Castria TB, Ramos MFKP, Dias AR, Cardili L, de Moraes RDR, Zilberstein B, Nahas SC, Ribeiro U, de Mello ES. Cytotoxic T-lymphocyte-associated protein 4 in gastric cancer: Prognosis and association with PD-L1 expression. J Surg Oncol. 2021 Dec.124(7):1040-1050. Pubmedid: 34255356.
    • de Castria TB, Tang L, Queiroz MM, Awni BM, Paroder V, Shamseddine A, Bariani GM, Mukherji D, Matar CF, Fernandes GDS, El-Olayan A, Sabatin F, Elias R, Gupta R, Janjigian YY, Abou-Alfa GK. Hepatoid esophagogastric adenocarcinoma and tumoral heterogeneity: a case report. J Gastrointest Oncol. 2021 Dec.12(6):3123-3132. Pubmedid: 35070435. Pmcid: PMC8748022.
    • Pereira MA, Ramos MFKP, Dias AR, Cardili L, Ribeiro RRE, de Castria TB, Zilberstein B, Nahas SC, Ribeiro U, de Mello ES. RhoA, Claudin 18, and c-MET in Gastric Cancer: Clinicopathological Characteristics and Prognostic Significance in Curative Resected Patients. Med Sci (Basel). 2021 Dec.10(1). Pubmedid: 35076580. Pmcid: PMC8788521.
    • Harada G, Bonadio RRDCC, de Araújo FCC, Victor CR, Sallum RAA, Junior UR, Cecconello I, Takeda FR, de Castria TB. Induction Chemotherapy for Locally Advanced Esophageal Cancer. J Gastrointest Cancer. 2020 Jun.51(2):498-505. Pubmedid: 31240598.
    • Ramos MFKP, Duarte VC, Pereira MA, de Castria TB, Schmerling CK, Zilberstein B, Ribeiro-Júnior U, Cecconello I. Schistosomiasis Misleading Gastric Cancer Treatment. J Gastrointest Cancer. 2020 Jun.51(2):643-646. Pubmedid: 31758467.
    • Vasconcellos VF, Marta GN, da Silva EM, Gois AF, de Castria TB, Riera R. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer. Cochrane Database Syst Rev. 2020 Jan.1(1):CD009256. Pubmedid: 31930743. Pmcid: PMC6956680.
    • Ramos MFKP, de Castria TB, Pereira MA, Dias AR, Antonacio FF, Zilberstein B, Hoff PMG, Ribeiro U, Cecconello I. Return to Intended Oncologic Treatment (RIOT) in Resected Gastric Cancer Patients. J Gastrointest Surg. 2020 Jan.24(1):19-27. Pubmedid: 31745892.
    • Ramos MFKP, Pereira MA, de Castria TB, Ribeiro RRE, Cardili L, de Mello ES, Zilberstein B, Ribeiro-Júnior U, Cecconello I. Remnant gastric cancer: a neglected group with high potential for immunotherapy. J Cancer Res Clin Oncol. 2020 Dec.146(12):3373-3383. Pubmedid: 32671505.
    • Charruf AZ, Ramos MFKP, Pereira MA, Dias AR, de Castria TB, Zilberstein B, Cecconelo I, Ribeiro U. Impact of neoadjuvant chemotherapy on surgical and pathological results of gastric cancer patients: A case-control study. J Surg Oncol. 2020 Apr.121(5):833-839. Pubmedid: 31943232.
    • Pereira MA, Ramos MFKP, Dias AR, Cardili L, Ribeiro RRE, Charruf AZ, de Castria TB, Zilberstein B, Ceconello I, Avancini Ferreira Alves V, Ribeiro U, de Mello ES. Lymph node regression after neoadjuvant chemotherapy: A predictor of survival in gastric cancer. J Surg Oncol. 2020 Apr.121(5):795-803. Pubmedid: 31773740.
    • Ramos MFKP, Pereira MA, Amorim LC, de Mello ES, Faraj SF, Ribeiro U, Hoff PMG, Cecconello I, de Castria TB. Gastric cancer molecular classification and adjuvant therapy: Is there a different benefit according to the subtype?. J Surg Oncol. 2020 Apr.121(5):804-813. Pubmedid: 31797380.
    • Victor CR, Fujiki FK, Takeda FR, Hoff PMG, de Castria TB. Safety and Effectiveness of Chemotherapy for Metastatic Esophageal Cancer in a Community Hospital in Brazil. J Glob Oncol. 2019 Jul.5:1-10. Pubmedid: 31365299. Pmcid: PMC6775989.
    • Pereira MA, Ramos MFKP, Dias AR, Faraj SF, Ribeiro RRE, de Castria TB, Zilberstein B, Alves VAF, Ribeiro U, de Mello ES. Expression Profile of Markers for Targeted Therapy in Gastric Cancer Patients: HER-2, Microsatellite Instability and PD-L1. Mol Diagn Ther. 2019 Dec.23(6):761-771. Pubmedid: 31595457.
    • Mota BS, Riera R, Ricci MD, Barrett J, de Castria TB, Atallah ÁN, Bevilacqua JL. Nipple- and areola-sparing mastectomy for the treatment of breast cancer. Cochrane Database Syst Rev. 2016 Nov.11(11):CD008932. Pubmedid: 27898991. Pmcid: PMC5868722.
    • Santos FN, de Castria TB, Cruz MR, Riera R. Chemotherapy for advanced non-small cell lung cancer in the elderly population. Cochrane Database Syst Rev. 2015 Oct.2015(10):CD010463. Pubmedid: 26482542. Pmcid: PMC6759539.
    • de Castria TB, Rodrigues SR, Diz Mdel P. Late isolated central nervous system relapse from ovarian serous adenocarcinoma: a case report and literature review. Case Rep Obstet Gynecol. 2014 Dec.2014:297307. Pubmedid: 25506007. Pmcid: PMC4251821.
    • de Castria TB, da Silva EM, Gois AF, Riera R. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer. Cochrane Database Syst Rev. 2013 Aug.(8):CD009256. Pubmedid: 23949842.
  • Patient Comments

    Overall Satisfaction


    107 patients rated this provider

    The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.

    Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

    Learn more about our patient satisfaction survey



    Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

    We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

    Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

    Learn more about our patient comments

    Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

    • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
    • He or she may be a researcher or other type of provider that does not see patients.
    • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.

    Learn more about our patient satisfaction survey, ratings and comments

  • In the News

    Dr. Tiago Biachi is on the medical review board at HealthCentral Corp. and has reviewed several articles related to gastrointestinal cancers.

Find a Doctor